title: Adaptation and antibiotic tolerance of anaerobic Burkholderia pseudomallei.
abstract: The Gram-negative bacterium Burkholderia pseudomallei is the etiological agent of melioidosis and is remarkably resistant to most classes of antibacterials. Even after months of treatment with antibacterials that are relatively effective in vitro, there is a high rate of treatment failure, indicating that this pathogen alters its patterns of antibacterial susceptibility in response to cues encountered in the host. The pathology of melioidosis indicates that B. pseudomallei encounters host microenvironments that limit aerobic respiration, including the lack of oxygen found in abscesses and in the presence of nitric oxide produced by macrophages. We investigated whether B. pseudomallei could survive in a nonreplicating, oxygen-deprived state and determined if this physiological state was tolerant of conventional antibacterials. B. pseudomallei survived initial anaerobiosis, especially under moderately acidic conditions similar to those found in abscesses. Microarray expression profiling indicated a major shift in the physiological state of hypoxic B. pseudomallei, including induction of a variety of typical anaerobic-environment-responsive genes and genes that appear specific to anaerobic B. pseudomallei. Interestingly, anaerobic B. pseudomallei was unaffected by antibacterials typically used in therapy. However, it was exquisitely sensitive to drugs used against anaerobic pathogens. After several weeks of anaerobic culture, a significant loss of viability was observed. However, a stable subpopulation that maintained complete viability for at least 1 year was established. Thus, during the course of human infection, if a minor subpopulation of bacteria inhabited an oxygen-restricted environment, it might be indifferent to traditional therapy but susceptible to antibiotics frequently used to treat anaerobic infections.
authors.affiliation: Department of Microbiology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA.
authors.forename: Mohamad A
authors.initials: MA
authors.lastname: Hamad
authors.forename: Chad R
authors.initials: CR
authors.lastname: Austin
authors.forename: Amanda L
authors.initials: AL
authors.lastname: Stewart
authors.forename: Mike
authors.initials: M
authors.lastname: Higgins
authors.forename: Andrés
authors.initials: A
authors.lastname: Vázquez-Torres
authors.forename: Martin I
authors.initials: MI
authors.lastname: Voskuil
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D016957:Burkholderia pseudomallei / Q000187:drug effects*; D002442:Ceftazidime / Q000494:pharmacology*; D006863:Hydrogen-Ion Concentration; D009593:Nitroimidazoles / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D009593:Nitroimidazoles; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D002442:Ceftazidime